Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | hypothetical protein | 0.0035 | 0.5929 | 0.5929 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.5929 | 0.5 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0044 | 0.8794 | 0.8794 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.2768 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0035 | 0.5929 | 0.6742 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0044 | 0.8794 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0044 | 0.8794 | 1 |
Brugia malayi | hypothetical protein | 0.0025 | 0.2768 | 0.2768 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0048 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0033 | 0.5371 | 0.6108 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.8794 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0048 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0044 | 0.8794 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.5929 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0044 | 0.8794 | 0.8794 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 0.5929 | 0.6742 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0025 | 0.2768 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0025 | 0.2768 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0035 | 0.5929 | 0.6742 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.8794 | 1 |
Brugia malayi | hypothetical protein | 0.0016 | 0.0147 | 0.0147 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.5371 | 0.5371 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.2768 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0025 | 0.2768 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 1 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0035 | 0.5929 | 0.6742 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0025 | 0.2768 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.2768 | 0.2768 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0025 | 0.2768 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0044 | 0.8794 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.5929 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0033 | 0.5371 | 0.5371 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0025 | 0.2768 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0035 | 0.5929 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0044 | 0.8794 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 1 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 1.13 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 2.9 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 3.02 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
Inhibition (functional) | = 53 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 83 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
Inhibition (functional) | = 98 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
Inhibition frequency index (IFI) (functional) | = 8.62 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 1 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 53 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 83 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
Percent growth inhibition (functional) | = 98 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
XC50 (functional) | = 6.14 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
XC50 (functional) | = 0.7181 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.